Text Size

Ventricular Wall Motion Characterization

This study is currently recruiting participants.
Verified July 2012 by St. Jude Medical
Sponsor:
Information provided by (Responsible Party):
St. Jude Medical
ClinicalTrials.gov Identifier:
NCT01629160
First received: June 24, 2012
Last updated: July 22, 2012
Last verified: July 2012
History of Changes
  Purpose

The purpose of this study is to evaluate feasibility of using new technologies to characterize ventricular wall motion in patients indicated for mapping and ablation procedures. Echo will be performed preoperatively and patients will receive a 1-month followup telephone call.


Condition
Atrial Fibrillation
Tachycardia, Ventricular

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Characterization of Normal and Abnormal Ventricular Wall Motion

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by St. Jude Medical:

Estimated Enrollment: 30
Study Start Date: July 2012
Estimated Primary Completion Date: November 2012 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Atrial Fibrillation or Ventricular Tachycardia

Criteria

Inclusion Criteria:

  • Be in sinus rhythm
  • Have the ability to provide informed consent for study participation and be willing and able to comply with the Clinical Investigational Plan described evaluations
  • Be undergoing mapping and ablation that requires left heart access for either ventricular tachycardia (VT) or atrial fibrillation (AF) according to HRS (Heart Rhythm Society)/ESC (European Society of Cardiology)/German National guidelines. The patient needs to have at least one of the following indications for left heart mapping and ablation to be included in the study: a) Symptomatic sustained monomorphic VT (SMVT), or b) Frequent PVCs, non-sustained VT, or VT that is presumed to cause ventricular dysfunction, or c) Bundle branch reentrant or interfascicular VTs, or d) Symptomatic AF with indication for ablation per current HRS/ESC/German National guidelines in a patient who is either 1) refractory or intolerant to at least one Class 1 or Class 3 antiarrhythmic medication, or 2) unable/unwilling to take antiarrhythmic drug therapy and chooses ablation as the first line of therapy

Exclusion Criteria:

  • Have permanent AF
  • Exhibit Cheyne-Stokes respiration
  • Have a recent myocardial infarction within 40 days prior to enrollment
  • Have undergone cardiac surgery or coronary revascularization procedure within 3 months prior to enrollment or be scheduled for such procedures
  • Have had a recent CVA or TIA within 3 months prior to enrollment
  • Be less than 18 years of age
  • Be pregnant
  • Be currently participating in any other clinical investigation
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01629160

Contacts
Contact: Gerhard Hindricks, MD +49 (341) 865 1413 hindg@medizin.uni-leipzig.de

Locations
Germany
Herzzentrum Leipzig GmbH Recruiting
Leipzig, Germany
Contact: Hindricks     +49 (341) 865 1413     hindg@medizin.uni-leipzig.de    
Sponsors and Collaborators
St. Jude Medical
Investigators
Principal Investigator: Gerhard Hindricks, MD Herzzentrum Leipzig GmbH
  More Information

No publications provided

Responsible Party: St. Jude Medical
ClinicalTrials.gov Identifier: NCT01629160     History of Changes
Other Study ID Numbers: 642
Study First Received: June 24, 2012
Last Updated: July 22, 2012
Health Authority: Germany: Federal Institute for Drugs and Medical Devices

Additional relevant MeSH terms:
Atrial Fibrillation
Tachycardia
Tachycardia, Ventricular
Arrhythmias, Cardiac
 Heart Diseases
Cardiovascular Diseases
Pathologic Processes

ClinicalTrials.gov processed this record on May 19, 2013